Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).
Lin Shen(Peking University), Caroline Germa(Novartis (United States)), Fuyou Zhao(Bengbu Medical College), Yanhong Deng(Sun Yat-sen University), Xueming Qian(Xi'an Jiaotong University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Zhixiang Zhuang(Soochow University), Yuxian Bai(Harbin Medical University), Meili Sun(Jinan Central Hospital), Ning Li(Henan Cancer Hospital), Hongli Li(Shanghai University of Traditional Chinese Medicine), Jiayi Li(First Affiliated Hospital of Xiamen University), Tianshu Liu(Sun Yat-sen University), Jianming Wang(China-Japan Friendship Hospital), Weijian Guo, Li Xu(Fujian Medical University), Charlie Qi, Zhenzhong Xia, Liang Han(Tianjin Medical University Cancer Institute and Hospital), Dan Liu(Huazhong University of Science and Technology)
Cited by 16
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k